# Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

> **NCT07420816** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Apsen Farmaceutica S.A.** · enrollment: 222 (estimated)

## Conditions studied

- Insomnia
- Insomnia Chronic

## Interventions

- **DRUG:** APSTZD 1
- **DRUG:** APSTZD 2
- **DRUG:** APSTZD 3
- **DRUG:** APSTZD 4
- **DRUG:** Stilnox CR®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07420816
- **Lead sponsor:** Apsen Farmaceutica S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2027-09-23
- **Final completion:** 2027-09-23
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07420816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07420816, "Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07420816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*